ACML AT SYGEN ORX EVENT 2024
The ACML team recently attended the launch event for Sygen Pharmaceuticals and ORx Pharmaceuticals Corporation, marking the establishment of their joint venture, Sygen-ORx Biosciences. The joint venture focuses on modifying generic drugs to enhance drug efficacy in therapeutic areas such as anti-malaria, antibiotics, anti-diabetes, and recuperative medicines.
By combining Sygen’s expertise in commercialization with ORx’s research capabilities, this partnership seeks to improve drug accessibility and foster innovation in healthcare. At Argentil, we are committed to supporting initiatives that create a lasting impact, and we believe that this collaboration will significantly advance healthcare not only in Nigeria but also within Sub Saharan Africa and beyond.
Kindly visit the link below for more information.
